Novartis Foundation

The Novartis Foundation is a nonprofit organization affiliated with Novartis and based in Basel, Switzerland. It forms part of the company’s corporate responsibility portfolio and works primarily on public-health and healthcare-access challenges in lower-income settings. Its projects have concentrated especially on sub-Saharan Africa and South Asia, with emphasis on infectious diseases, primary healthcare, and the strengthening of local health systems. The foundation’s work grew out of a longer tradition of humanitarian and international-development engagement by Basel’s pharmaceutical and chemical companies. In the 1960s, Ciba, Geigy, Sandoz, Durand & Huguenin, Hoffmann-La Roche, and Lonza were among the companies involved in establishing the Basel Foundation for Developing Countries. That organization supported development and health initiatives, including assistance to the field laboratory of the Swiss Tropical Institute in Ifakara, Tanzania. The institution, now known as the Ifakara Health Institute, remains associated with the history of this development-oriented work. The foundation’s contemporary focus includes leprosy, malaria, access to healthcare, and the improvement of primary-care delivery. Rather than operating solely as a direct service provider, it has positioned itself as a facilitator among pharmaceutical companies, governments, nongovernmental organizations, research institutions, and civil-society groups. This convening role allows it to support policy discussions, pilot programs, research partnerships, and efforts to make healthcare delivery more sustainable at the local level. Its access-to-healthcare activities are intended to address both the availability of services and the capacity of health systems to deliver them. This includes attention to primary healthcare and to the institutional conditions required for effective prevention, diagnosis, treatment, and referral. The foundation has also promoted exchange among practitioners and policymakers through an international symposium held in Basel. The Novartis Foundation should be distinguished from an earlier scientific and educational organization that also used the Novartis Foundation name. That separate London-based institution was founded in 1949 by Ciba, later adopted the Novartis name after the Ciba–Sandoz merger, and was dissolved in 2008 after merging with the Academy of Medical Sciences. The subject covered here is the Basel-based development and global-health foundation described by the canonical Wikipedia article.

The Novartis Foundation’s background lies in the international-development and humanitarian activities of Basel’s pharmaceutical and chemical sector. During the 1960s, Ciba, Geigy, Sandoz, Durand & Huguenin, Hoffmann-La Roche, and Lonza were involved in founding the Basel Foundation for Developing Countries. The organization provided support for development-related health work, including the field laboratory of the Swiss Tropical Institute in Ifakara, Tanzania. That laboratory later developed into the Ifakara Health Institute, which continued to maintain links with the foundation’s development tradition. Following the creation of Novartis through the merger of Ciba-Geigy and Sandoz, the development-oriented organization became associated with the Novartis name and was known as the Novartis Foundation for Sustainable Development. It subsequently became known more simply as the Novartis Foundation. The foundation was established as a nonprofit body within the broader corporate-responsibility activities connected with Novartis, while maintaining a focus on international health and development rather than commercial pharmaceutical operations. Over time, the foundation concentrated its work on countries and communities where limited resources, weak infrastructure, and infectious diseases create barriers to effective healthcare. Its principal geographic emphasis has been sub-Saharan Africa and the Indian subcontinent, although its partnerships and policy discussions have had an international scope. Its program areas have included leprosy, malaria, access to healthcare, primary-care delivery, and the strengthening of local health systems. The organization’s operating model emphasizes collaboration. It has sought to act as an intermediary among private companies, public authorities, nongovernmental organizations, research bodies, and civil-society organizations. This approach reflects the foundation’s view that improvements in population health require more than medicines alone: they also depend on health-worker capacity, local institutions, financing, public policy, reliable delivery systems, and cooperation among stakeholders. The foundation has also supported health-policy dialogue and organized an international symposium in Basel. These activities provide a forum for sharing evidence and discussing practical approaches to healthcare access and system development. Its work therefore combines project support with convening, partnership-building, and policy-oriented activity. The name Novartis Foundation has also been used by a separate scientific and educational charity. That institution originated in 1949 as the Ciba Foundation, later adopted the Novartis name, and organized medical-science symposia in London and elsewhere. Novartis withdrew financial support from it in February 2008; the trustees subsequently merged it with the Academy of Medical Sciences on 31 July 2008, and the foundation was dissolved later that year. This London scientific foundation is distinct from the Basel-based global-health and development organization represented by this dossier.

• 2008

  Separate London scientific foundation dissolved

  [1]Novartis Foundationen.wikipedia.org

  A distinct scientific and educational organization using the Novartis Foundation name merged with the Academy of Medical Sciences and was dissolved later in the year. This event did not end the Basel-based development foundation described in this entry.

• 1996

  Novartis created through the Ciba–Sandoz merger

  [1]Novartis Foundationen.wikipedia.org

  The merger that created Novartis established the corporate context in which the development-focused foundation became associated with the Novartis name.

• 1960

  Basel development foundation established

  [1]Novartis Foundationen.wikipedia.org

  Basel-based pharmaceutical and chemical companies, including Ciba, Geigy, Sandoz, Hoffmann-La Roche, Durand & Huguenin, and Lonza, were involved in founding the Basel Foundation for Developing Countries, an institutional predecessor in the foundation’s development-oriented history.

A corporate-affiliated global-health and development foundation that connects the private sector, governments, civil society, nongovernmental organizations, and research institutions to improve healthcare access and strengthen health systems.

• Global health program

  Leprosy initiatives

  Programs addressing leprosy form one of the foundation’s central disease-focused areas. They sit within its broader effort to improve access to diagnosis, treatment, and supportive health services in settings where infectious diseases and limited healthcare infrastructure continue to affect vulnerable populations.

• Global health program

  Malaria initiatives

  The foundation supports work related to malaria as part of its international public-health portfolio. Its contribution is associated with broader health-system and access objectives, linking disease control with local healthcare capacity, public-sector coordination, and the availability of primary-care services.

• Healthcare development program

  Healthcare-access projects

  Healthcare-access projects focus on improving the availability and reach of primary healthcare, particularly in sub-Saharan Africa and South Asia. The foundation works through partnerships intended to strengthen local delivery systems and to connect public institutions, civil society, researchers, and private-sector participants.

• Policy and knowledge exchange

  International health symposium

  The foundation organizes an international symposium in Basel to encourage discussion of global-health policy and practice. The event supports exchange among stakeholders from government, civil society, research institutions, and the private sector, complementing the foundation’s field-based and partnership activities.

1. 1Novartis Foundationen.wikipedia.org